Cargando…
Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition
Alcohol consumption is internationally recognized as one of the compelling risk factors for breast cancer, but it does not necessarily correlate with the prognosis of breast cancer patients. Alcohol consumption in breast cancer patients was addressed in the 2022 Breast Cancer Clinical Practice Guide...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284729/ https://www.ncbi.nlm.nih.gov/pubmed/37029889 http://dx.doi.org/10.1007/s12282-023-01455-4 |
_version_ | 1785061463485841408 |
---|---|
author | Nomura, Tsunehisa Kawai, Masaaki Fukuma, Yuna Koike, Yoshikazu Ozaki, Shinji Iwasaki, Motoki Yamamoto, Seiichiro Takamatsu, Kiyoshi Okamura, Hitoshi Arai, Masami Ootani, Shoichiro Iwata, Hiroji Saji, Shigehira |
author_facet | Nomura, Tsunehisa Kawai, Masaaki Fukuma, Yuna Koike, Yoshikazu Ozaki, Shinji Iwasaki, Motoki Yamamoto, Seiichiro Takamatsu, Kiyoshi Okamura, Hitoshi Arai, Masami Ootani, Shoichiro Iwata, Hiroji Saji, Shigehira |
author_sort | Nomura, Tsunehisa |
collection | PubMed |
description | Alcohol consumption is internationally recognized as one of the compelling risk factors for breast cancer, but it does not necessarily correlate with the prognosis of breast cancer patients. Alcohol consumption in breast cancer patients was addressed in the 2022 Breast Cancer Clinical Practice Guidelines. A systematic review and meta-analysis of epidemiological studies on alcohol consumption and breast cancer recurrence, breast cancer-related mortality, all-cause mortality, and cardiovascular disease mortality in breast cancer patients was performed. The PubMed, Cochrane Library, and Ichushi-Web databases were searched for relevant publications reporting cohort or case–control studies published until March 2021. A total of 33 studies (32 cohort studies and 1 case–control study) met the eligibility criteria; 4638 cases of recurrence, 12,209 cases of breast cancer-specific mortality, and 21,945 cases of all-cause mortality were observed. With regard to breast cancer recurrence, 7 studies assessed pre-diagnosis alcohol consumption (relative risk (RR) 1.02, 95% confidence interval (95% CI) 0.77–1.37, p = 0.88) and 3 studies assessed post-diagnosis alcohol consumption (RR 0.96, 95% CI 0.85–1.10, p = 0.57), and no significant increase or decrease in risk was observed. With regard to breast cancer-related mortality, 19 studies assessed pre-diagnosis alcohol consumption (RR 1.02, 95% CI 0.93–1.11, p = 0.69), 9 studies assessed post-diagnosis alcohol consumption (RR 0.96, 95% CI 0.77–1.19, p = 0.70), and no significant increase or decrease in risk was observed. With regard to all-cause mortality, 18 studies assessed pre-diagnosis alcohol consumption (RR 0.90, 95% CI 0.82–0.99, p = 0.02), 8 studies assessed post-diagnosis alcohol consumption (RR 0.88, 95% CI 0.74–1.02, p = 0.08), and pre-diagnosis alcohol consumption was associated with a significantly decreased risk. With regard to cardiovascular disease mortality and alcohol consumption, 2 studies assessed it, and the RRwas 0.47 (95% CI 0.28–0.79, p = 0.005), showing that alcohol consumption was associated with a significantly decreased risk. The limitations of this study are that drinking status was mainly based on a questionnaire survey, which is somewhat inaccurate and has many confounding factors, and the cut-off value for the maximum alcohol intake in many studies was low, and it is possible that the actual intake was only an appropriate amount. In many countries, a standard drinking amount is set, and wise decisions are required. |
format | Online Article Text |
id | pubmed-10284729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-102847292023-06-23 Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition Nomura, Tsunehisa Kawai, Masaaki Fukuma, Yuna Koike, Yoshikazu Ozaki, Shinji Iwasaki, Motoki Yamamoto, Seiichiro Takamatsu, Kiyoshi Okamura, Hitoshi Arai, Masami Ootani, Shoichiro Iwata, Hiroji Saji, Shigehira Breast Cancer Special Article Alcohol consumption is internationally recognized as one of the compelling risk factors for breast cancer, but it does not necessarily correlate with the prognosis of breast cancer patients. Alcohol consumption in breast cancer patients was addressed in the 2022 Breast Cancer Clinical Practice Guidelines. A systematic review and meta-analysis of epidemiological studies on alcohol consumption and breast cancer recurrence, breast cancer-related mortality, all-cause mortality, and cardiovascular disease mortality in breast cancer patients was performed. The PubMed, Cochrane Library, and Ichushi-Web databases were searched for relevant publications reporting cohort or case–control studies published until March 2021. A total of 33 studies (32 cohort studies and 1 case–control study) met the eligibility criteria; 4638 cases of recurrence, 12,209 cases of breast cancer-specific mortality, and 21,945 cases of all-cause mortality were observed. With regard to breast cancer recurrence, 7 studies assessed pre-diagnosis alcohol consumption (relative risk (RR) 1.02, 95% confidence interval (95% CI) 0.77–1.37, p = 0.88) and 3 studies assessed post-diagnosis alcohol consumption (RR 0.96, 95% CI 0.85–1.10, p = 0.57), and no significant increase or decrease in risk was observed. With regard to breast cancer-related mortality, 19 studies assessed pre-diagnosis alcohol consumption (RR 1.02, 95% CI 0.93–1.11, p = 0.69), 9 studies assessed post-diagnosis alcohol consumption (RR 0.96, 95% CI 0.77–1.19, p = 0.70), and no significant increase or decrease in risk was observed. With regard to all-cause mortality, 18 studies assessed pre-diagnosis alcohol consumption (RR 0.90, 95% CI 0.82–0.99, p = 0.02), 8 studies assessed post-diagnosis alcohol consumption (RR 0.88, 95% CI 0.74–1.02, p = 0.08), and pre-diagnosis alcohol consumption was associated with a significantly decreased risk. With regard to cardiovascular disease mortality and alcohol consumption, 2 studies assessed it, and the RRwas 0.47 (95% CI 0.28–0.79, p = 0.005), showing that alcohol consumption was associated with a significantly decreased risk. The limitations of this study are that drinking status was mainly based on a questionnaire survey, which is somewhat inaccurate and has many confounding factors, and the cut-off value for the maximum alcohol intake in many studies was low, and it is possible that the actual intake was only an appropriate amount. In many countries, a standard drinking amount is set, and wise decisions are required. Springer Nature Singapore 2023-04-08 2023 /pmc/articles/PMC10284729/ /pubmed/37029889 http://dx.doi.org/10.1007/s12282-023-01455-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Special Article Nomura, Tsunehisa Kawai, Masaaki Fukuma, Yuna Koike, Yoshikazu Ozaki, Shinji Iwasaki, Motoki Yamamoto, Seiichiro Takamatsu, Kiyoshi Okamura, Hitoshi Arai, Masami Ootani, Shoichiro Iwata, Hiroji Saji, Shigehira Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition |
title | Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition |
title_full | Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition |
title_fullStr | Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition |
title_full_unstemmed | Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition |
title_short | Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition |
title_sort | alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the japanese breast cancer society clinical practice guideline, 2022 edition |
topic | Special Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10284729/ https://www.ncbi.nlm.nih.gov/pubmed/37029889 http://dx.doi.org/10.1007/s12282-023-01455-4 |
work_keys_str_mv | AT nomuratsunehisa alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT kawaimasaaki alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT fukumayuna alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT koikeyoshikazu alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT ozakishinji alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT iwasakimotoki alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT yamamotoseiichiro alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT takamatsukiyoshi alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT okamurahitoshi alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT araimasami alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT ootanishoichiro alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT iwatahiroji alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition AT sajishigehira alcoholconsumptionandbreastcancerprognosisafterbreastcancerdiagnosisasystematicreviewandmetaanalysisofthejapanesebreastcancersocietyclinicalpracticeguideline2022edition |